Le Lézard6h
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
DUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 ...
Business Insider16h
Ocugen’s Promising Gene Therapy Advancements and Financial Stability Justify Buy Rating
The company is making significant strides in its gene therapy programs, particularly with its lead program, OCU400, which targets retinitis pigmentosa (RP). The therapy has shown ... The anticipation ...
Repligen: Q3 Earnings Snapshot
The drug developer posted revenue of $154.9 million in the period, also exceeding Street forecasts. Six analysts surveyed by Zacks expected $153.1 million. Repligen expects full-year earnings in the ...
Business Insider21h
Ludo Unveils Decentralized Reputation Layer to Enhance Trust Across Web3
With successful ventures such as EuroDNS, the leading European domain registrar, and GeoRanker, a global brand recognized for its leadership in data acquisition and reputation analytics, they have ...
yourinvestmentpropertymag.com.au3h
Newcastle, 2300
Contains property sales information provided under licence from the Valuer General New South Wales. RP Data Pty Ltd trading as CoreLogic Asia Pacific is authorised as a Property Sales Information ...
yourinvestmentpropertymag.com.au3h
Yamba, 2464
Contains property sales information provided under licence from the Valuer General New South Wales. RP Data Pty Ltd trading as CoreLogic Asia Pacific is authorised as a Property Sales Information ...